Journal
NEUROLOGY
Volume 78, Issue 18, Pages 1390-1393Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e318253d61e
Keywords
-
Categories
Funding
- NIH [T32 AI07387-21, R01 NS047029, CA115745, EB004582, MH80729, MH077073, DC008796, NS047029, CA101942, AG031720, AG028076, DK084463, R56 NS 041198, K24 NS 060950]
- GE Healthcare
- Siemens Medical
- Department of Defense [SC090251]
- Biogen Idec
- National Multiple Sclerosis Society
- Bristol Myers Squibb
- Ono Pharmaceuticals
- Merck Serono
- Hoffmann La Roche
- GlaxoSmithKline
- Perseid Therapeutics
- Vertex Pharmaceutical
- Johnson Johnson
- UpToDate
Ask authors/readers for more resources
Objective: Progressive multifocal leukoencephalopathy (PML) is a severe complication of natalizumab therapy in patients with multiple sclerosis (MS), which is often accompanied by an immune reconstitution inflammatory syndrome (IRIS) after removal of the drug. We describe a patient with MS who presented with simultaneous PML-IRIS 2 months after stopping natalizumab for other reasons. Case Report and Results: The patient had widespread PML and severe IRIS. He received corticosteroids and displayed a vigorous JC virus-specific cellular immune response. Elevated myoinositol and lipid/creatine peaks measured in PML lesions by proton magnetic resonance spectroscopy (H-1-MRS) corresponded to episodes of contrast enhancement on MRI scans and persisted after the enhancement subsided. He demonstrated steady clinical improvement, but developed marked residual atrophy in areas affected by PML and inflammation, as well as seizures. Conclusions: New enhancing white matter lesions, occurring after discontinuation of natalizumab, can be the manifestation of PML-IRIS rather than an MS exacerbation. Elevated myoinositol and lipid/creatine peaks appear to be more sensitive markers of inflammation in PML lesions than contrast enhancement. H-1-MRS may become useful as a biomarker for PML-IRIS by helping clinicians determine the need for corticosteroid administration and anticipate continuing clinical recovery. Neurology (R) 2012;78:1390-1393
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available